e-Therapeutics plc Senior Management Update (8337M)

TIDMETX

RNS Number : 8337M

e-Therapeutics plc

20 September 2023

e-therapeutics plc

("e-therapeutics" or the "Company")

Senior Management Update

London, UK, 20 September 2023 - e-therapeutics plc (AIM: ETX; OTCQX; ETXPF), a company integrating computational power and biological data to discover life-transforming RNAi medicines, announces that Michael Bretherton has stepped down from his role as interim CFO and will now focus on his role as a Non-Executive Director of the Company. Timothy Bretherton, Director of Finance and Operations, will assume the CFO role (non-board) with immediate effect.

Timothy is an experienced finance leader having held multiple senior roles prior to joining e-therapeutics in May 2022. He has a strong practical background previously gained over 12 years in operational and finance roles including four years as a consultant at PwC and three years as an auditor at Mazars. He has a degree in Economics from the University of Leicester and is a member of the Institute of Chartered Accountants in England and Wales.

Ali Mortazavi, Chief Executive Officer of e-therapeutics, commented:

"It is with great pleasure that I appoint Tim as CFO. Tim has demonstrated exceptional dedication and expertise during his time with e-therapeutics and I look forward to continuing to work with him to deliver our strategic objectives."

Enquiries:

 
    e-therapeutics plc 
    Ali Mortazavi, CEO                             Tel: +44 (0)20 4551 
     Timothy Bretherton, CFO                        8888 
                                                    www.etherapeutics.co.uk 
------------------------------------------------  ------------------------- 
 
     SP Angel Corporate Finance LLP                Tel: +44(0)20 3470 
                                                    0470 
    Nominated Adviser and Broker 
    Matthew Johnson/Harry Davies-Ball (Corporate 
     Finance) 
    Vadim Alexandre/Rob Rees (Corporate Broking) 
------------------------------------------------  -------------------------

About e-therapeutics plc

e-therapeutics plc ("ETX") integrates computational power and biology information to discover life-transforming RNAi medicines. The Company's technology uses computation to capture and model human biology, identify novel targets, and develop RNAi medicines against those targets that can be rapidly progressed to the clinic.

ETX's proprietary HepNetTM platform enables the generation and analysis of biological network models, providing a novel and mechanistic approach to drug discovery. This approach explicitly considers the true complexity of biology to make more reliable predictions from large complex data sets and ETX's proprietary hepatocyte knowledge base - the world's most comprehensive and integrated hepatocyte-centric data resource. The Company generates, prioritises and tests millions of hypotheses in silico to identify better therapeutic targets with higher confidence.

GalOmicTM, ETX's proprietary RNAi platform, enables the targeted delivery to hepatocytes in the liver and the specific silencing of novel disease-associated genes, identified by HepNetTM. The focus on hepatocytes offers the opportunity to tackle a wide variety of diseases. The liver is a highly metabolically active organ which performs a key role in many biological processes and vital functions crucial for human health. ETX's GalOmicTM constructs have demonstrated compelling in vivo performance in terms of depth of gene silencing and duration of action.

The Company is progressing a pipeline of first-in-class preclinical RNAi candidates across several high unmet medical needs in cardiometabolic indications and targeting promising hepatocyte-expressed targets with effects in other disease areas. ETX has also partnered with biopharma companies such as Novo Nordisk, Galapagos NV and iTeos Therapeutics using its computational network biology approach across a diverse range of drug discovery projects.

The Company is based in London, UK and listed on the Alternative Investment Market of the London Stock Exchange ("AIM"), with ticker symbol ETX. E-therapeutics is also traded on the OTCQX Best Market (OTCQX) in the United States, under ticker symbol ETXPF.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCNKFBPFBKDPCD

(END) Dow Jones Newswires

September 20, 2023 02:00 ET (06:00 GMT)

E-therapeutics (LSE:ETX)
Graphique Historique de l'Action
De Nov 2024 à Déc 2024